Mooney, Jessica and Price, Jessica and Bain, Carolyn and Bawa, John Tanko and Gurley, Nikki and Kumar, Amresh and Liyanage, Guwani and Mkisi, Rouden Esau and Odero, Chris and Seck, Karim and Simpson, Evan and Hausdorff, William P. and Dida, Gabriel O. (2022) Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries. PLOS ONE, 17 (6). e0270369. ISSN 1932-6203
journal.pone.0270369.pdf - Published Version
Download (701kB)
Abstract
Background
Live oral rotavirus vaccines (LORVs) have significantly reduced rotavirus hospitalizations and deaths worldwide. However, LORVs are less effective in low- and middle-income countries (LMICs). Next-generation rotavirus vaccines (NGRVs) may be more effective but require administration by injection or a neonatal oral dose, adding operational complexity. Healthcare providers (HPs) were interviewed to assess rotavirus vaccine preferences and identify delivery issues as part of an NGRV value proposition.
Objective
Determine HP vaccine preferences about delivering LORVs compared to injectable (iNGRV) and neonatal oral (oNGRV) NGRVs.
Methods
64 HPs from Ghana, Kenya, Malawi, Peru, and Senegal were interviewed following a mixed-method guide centered on three vaccine comparisons: LORV vs. iNGRV; LORV vs. oNGRV; oNGRV vs. iNGRV. HPs reviewed attributes for each vaccine in the comparisons, then indicated and explained their preference. Additional questions elicited views about co-administering iNGRV+LORV for greater public health impact, a possible iNGRV-DTP-containing combination vaccine, and delivering neonatal doses.
Results
Almost all HPs preferred oral vaccine options over iNGRV, with many emphasizing an aversion to additional injections. Despite this strong preference, HPs described challenges delivering oral doses. Preferences for LORV vs. oNGRV were split, marked by disparate views on rotavirus disease epidemiology and the safety, need, and feasibility of delivering neonatal vaccines. Although overwhelmingly enthusiastic about an iNGRV-DTP-containing combination option, several HPs had concerns. HP views were divided on the feasibility of co-administering iNGRV+LORV, citing challenges around logistics and caregiver sensitization.
Conclusion
Our findings provide valuable insights on delivering NGRVs in routine immunization. Despite opposition to injectables, openness to co-administering LORV+iNGRV to improve efficacy suggests future HP support of iNGRV if adequately informed of its advantages. Rationales for LORV vs. oNGRV underscore needs for training on rotavirus epidemiology and stronger service integration. Expressed challenges delivering existing LORVs merit further examination and indicate need for improved delivery.
Item Type: | Article |
---|---|
Subjects: | Institute Archives > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 11 Feb 2023 04:40 |
Last Modified: | 17 Jul 2024 07:17 |
URI: | http://eprint.subtopublish.com/id/eprint/1318 |